Use of transfer factor in immunosuppressed surgical patients.
to evaluate the action of Transfer Factor on the immune response of patients with malignant neoplasm submitted to surgery, chemotherapy and radiotherapy. we analyzed the variations of leukocytes, total lymphocytes, T-lymphocytes and CD4 counts in 60 patients submitted to immunostimulation with a single, daily dose of 0.5mg sublingual Transfer Factor, started simultaneously with chemotherapy and/or radiotherapy. there were statistically significant increases in the counts of all cell lines studied, more pronounced after 12 months of use of the medication. the Transfer Factor restored immune response and showed no side effects.